Compare PSQH & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSQH | BYSI |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3M | 31.4M |
| IPO Year | 2021 | 2016 |
| Metric | PSQH | BYSI |
|---|---|---|
| Price | $5.48 | $0.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.8K | ★ 80.2K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,685,987.00 | N/A |
| Revenue This Year | $80.20 | N/A |
| Revenue Next Year | $34.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1096.61 | N/A |
| 52 Week Low | $0.36 | $0.57 |
| 52 Week High | $6.94 | $2.44 |
| Indicator | PSQH | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 55.95 | 49.07 |
| Support Level | $4.71 | $0.58 |
| Resistance Level | $5.71 | $0.80 |
| Average True Range (ATR) | 0.32 | 0.05 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 63.46 | 74.49 |
PSQ Holdings Inc operates the website and mobile application named as PublicSq. It is an app and website that connects freedom-loving Americans to high-quality businesses that share values, both online and in local communities. It has three reportable segments comprised of Marketplace; which includes a marketplace platform to access consumers that are drawn to patriotic values and the revenue is generated in the form of advertising and eCommerce transactions, and Brands segment in which through its wholly-owned brand, the company generates revenue from online sales of diapers and wipes and third financial technology which assists consumers, lenders, and retailers in offering point-of-sale financing products.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.